Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial - Clinical Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
ESMO: Kisqali shows superior overall survival in breast cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow
YIR On Demand Breast Hope S Rugo, MD Professor of Medicine - ppt download
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
BOOG Study Center - Studie
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
MONALEESA-3: Updated Survival
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 | Journal of Clinical Oncology
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
![PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/209632dabf2da4cb7603c235e661f27e804de4df/4-Figure2-1.png "PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar")
PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
